Q2 2024 EPS Estimates for Chimerix, Inc. (NASDAQ:CMRX) Decreased by Analyst

Chimerix, Inc. (NASDAQ:CMRX) – Equities researchers at HC Wainwright decreased their Q2 2024 earnings per share estimates for Chimerix in a note issued to investors on Thursday, May 2nd. HC Wainwright analyst E. White now expects that the biopharmaceutical company will post earnings per share of ($0.23) for the quarter, down from their prior forecast of ($0.22). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Chimerix’s Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.96) EPS, FY2025 earnings at ($1.07) EPS and FY2026 earnings at ($1.01) EPS.

Other research analysts have also recently issued reports about the company. StockNews.com cut Chimerix from a “hold” rating to a “sell” rating in a research note on Friday. Wedbush reaffirmed an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research note on Monday, February 12th.

Chimerix Trading Up 4.9 %

Shares of NASDAQ:CMRX opened at $1.00 on Monday. The stock’s 50-day moving average price is $1.04 and its 200-day moving average price is $1.00. Chimerix has a 12-month low of $0.88 and a 12-month high of $1.57. The stock has a market capitalization of $89.63 million, a P/E ratio of -1.08 and a beta of 1.13.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. During the same period in the previous year, the company posted ($0.24) EPS.

Institutional Trading of Chimerix

Large investors have recently modified their holdings of the business. Vance Wealth Inc. bought a new stake in shares of Chimerix in the fourth quarter worth about $46,000. Pale Fire Capital SE bought a new stake in shares of Chimerix in the third quarter worth about $95,000. Assenagon Asset Management S.A. grew its stake in shares of Chimerix by 167.3% in the third quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock worth $410,000 after purchasing an additional 267,044 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Chimerix by 190.0% in the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 387,638 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in Chimerix during the 4th quarter valued at approximately $1,348,000. 45.42% of the stock is owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.